France’s ANSM Issues Warning Against Unauthorized Stem Cell Therapies Promoted Online

France’s national medicines safety agency has issued a public warning regarding unauthorized stem cell therapy advertisements targeting patients with serious and degenerative medical conditions. The Agence nationale de sécurité du médicament (ANSM) flagged two foreign-operated websites promoting unverified regenerative treatments for diseases including Alzheimer’s, Parkinson’s, and Charcot’s disease, according to an official statement published by the regulator (La Dépêche).

The regulatory action centers on online platforms operated by Liv Hospital and You StemCell, both based in Turkey. According to the ANSM, these commercial entities have been marketing cell-based treatments directly to patients in France without holding the mandatory marketing authorizations required under French and European Union laws (Doctissimo). Officials stress that the advertised procedures—which claim to treat conditions such as autism, multiple sclerosis, and cerebral palsy—lack clinical proof of efficacy, quality, and safety.

The safety agency has launched health police measures to suspend the illicit promotions, while urging affected individuals to consult legitimate medical professionals immediately.

ANSM Targets Foreign Clinics Promoting Unverified Treatments

The regulatory intervention specifically targets online outreach directed at French residents by Liv Hospital and You StemCell. In a public advisory issued on August 10, the ANSM stated that these foreign providers “affirment de manière infondée que les thérapies qu’elles proposent soignent des maladies graves comme l’autisme, la paralysie cérébrale, la sclérose en plaques, Alzheimer, maladie de Charcot”.

Beyond lacking valid marketing authorizations, neither company holds an advertising visa issued by the ANSM. The promotion of stem cell interventions, whether utilized alone or in conjunction with exosomes, falls squarely under pharmaceutical regulations that require comprehensive clinical trials before commercial marketing can occur (Doctissimo).

Patient Risks and Regulatory Guidance

Beyond direct physical complications stemming from unmonitored biological interventions, patients face the severe danger of a “perte de chance”—a clinical loss of opportunity caused by delaying or abandoning established therapies validated by public health authorities.

The ANSM advises anyone who has engaged with these online platforms or undergone proposed treatments to contact their regular healthcare providers immediately. Patients should disclose all therapeutic acts performed and formally report any adverse events experienced through national safety reporting channels.

Understanding Cellular Therapy and Regulatory Standards

To contextualize the warning, public health research bodies like the Institut national de la santé et de la recherche médicale (Inserm) define cellular therapy as the introduction of live cells into a patient’s body to prevent or treat illness or regenerate damaged tissues (La Dépêche). These techniques generally utilize stem cells, immune cells, or mature somatic cells derived from the patient or a donor.

While legitimate regenerative medicine holds documented potential in oncology and immunology, authorized clinical applications require strict peer-reviewed evaluation. The European regulatory framework ensures that no cellular product reaches the market without definitive proof that its benefits outweigh its risks.